Actelion issues invitation to 2015 Annual General Meeting of Shareholders
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion issues invitation to 2015 Annual General Meeting of Shareholders
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 10 April 2015 - Actelion Ltd (SIX: ATLN) today
issued the formal invitation to the upcoming Annual General Meeting (AGM) of
Shareholders on behalf of the Board of Directors. The meeting will take place on
Friday, 8 May 2015 (10:00hrs CEST) at the Congress Center, Messe Basel,
Switzerland.
At this year's meeting the Board of Directors is proposing an increase in the
dividend payment to CHF 1.30 per share. Also, following the approval of the
Articles of Association at the 2014 AGM, the Board is proposing for the first
time the approval of a maximum compensation for the non-executive members of the
Board of Directors and the maximum compensation amount for the Actelion
Executive Committee.
After 10 and 15 years of service on Actelion's Board of Directors, respectively,
Mr. Carl Feldbaum and Mr. Werner Henrich will be stepping down at the AGM. All
other Board members will stand for re-election.
Jean-Pierre Garnier, Chairman of the Board of Directors, commented: "Personally,
I enjoyed working with both Carl and Werner, who have greatly supported Actelion
during their long service as integral members on Actelion's Board of Directors.
Their individual contributions to the success of Actelion will be duly
celebrated at the AGM."
In addition to the regular agenda items, the Board is proposing the election of
two new Directors: Mrs. Herna Verhagen, Chief Executive Officer of PostNL N.V.,
and Mr. David Stout, a pharmaceutical industry professional who has announced
his resignation from the Board of Shire, plc. at the end of April 2015.
Jean-Pierre Garnier, concluded: "As a current CEO of a company with a very
complex business model, Herna understands the challenges of operating in the
current economic and business climate. David brings a broad experience of the
pharmaceutical business having spent his entire professional career in global
pharma. I am confident that both professionals will make a significant
contribution to Actelion, should our shareholders decide to elect them to the
Board."
NOTES TO SHAREHOLDERS
The Annual General Meeting of Shareholders to approve the Business Report of the
year ending 31 December 2014 will be held on 8 May 2015 at 10.00 CEST at the
Congress Center, Messe Basel, Switzerland.
The invitation was published in the Swiss Official Gazette of Commerce
(Schweizerisches Handelsamtsblatt) on 10 April 2015 and is available, together
with the Company's Annual Report, on www.actelion.com/agm.
In order to attend and vote at the Annual General Meeting of Shareholders,
Shareholders must have been registered in the Company's shareholder register by
27 April 2015 at the latest.
###
NOTES TO EDITORS
AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2015
1. Annual Report 2014, Consolidated Accounts 2014, Statutory Accounts 2014 and
Compensation Report 2014
1.1. Approval of Annual Report 2014, Consolidated Financial Statements
2014 and Statutory Financial Statements 2014
1.2. Consultative Vote on the Compensation Report 2014
2. Appropriation of Available Earnings and Distribution Against Reserve from
Capital Contribution
3. Discharge of the Board of Directors and of the Executive Management
4. Board Elections
4.1. Re-Election of the Board of Directors
4.2. Election of New Directors
4.3. Election of the Chairperson of the Board of Directors
4.4. Election of the Compensation Committee
5. Approval of Board Compensation and Executive Management Compensation
5.1. Approval of Board Compensation (Non-Executive Directors)
5.2. Approval of Executive Management Compensation 2016 (Maximum Amount)
6. Election of Independent Proxy
7. Election of the Statutory Auditors
BIOGRAPHIES OF PROPOSED NEW DIRECTORS
Ms. Herna Verhagen
Herna Verhagen (49), a Dutch citizen, became Chief Executive Officer of PostNL
N.V., a mail, parcel and e-commerce corporation, in April 2012.
Prior to this Ms. Verhagen served as member of the Board of Management of PostNL
N.V. and held various executive positions within the Group. Ms. Verhagen's
portfolio includes corporate strategy, public affairs, communications, corporate
responsibility, human resources and internal audit.
Ms. Verhagen holds a MSc in Human Resource Studies and a LLM in Business Law.
Ms. Verhagen also serves in the Supervisory Board of Rexel S.A. and is a member
of the Executive Committee and General Board of the Confederation of Netherlands
Industry and Employers (VNO-NCW).
Mr. David Stout
David Stout (60), a US citizen, was President, Pharmaceutical Operations at
GlaxoSmithKline, where he was responsible for the company's global
pharmaceutical operations from 2003 to 2008.
Prior to this Mr. Stout was President of GlaxoSmithKline's US pharmaceuticals
business and before that SmithKline Beecham's North American pharmaceuticals
business. Before joining SmithKline Beecham, Mr. Stout worked for many years at
Schering-Plough. With over 20 years of senior management experience, Mr. Stout
brings extensive international sales, marketing, operational and supply chain
experience of the pharmaceutical industry.
Mr. Stout holds a BA in Biology. He serves on the Boards of the public companies
Airgas, Inc. and Jabil, Inc. and the non-public company NanoBio Corporation. He
has served on the Board of Shire, Plc. from 2010 until 2015 and will not stand
for re-election at their AGM in April.
Actelion Ltd.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell
lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks
are legally protected.
For further information please contact:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
http://hugin.info/131801/R/1909746/680903.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1909746]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Rye Patch Hires Lincoln Hill Project TeamDatum: 10.04.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 384786
Anzahl Zeichen: 10513
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 141 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion issues invitation to 2015 Annual General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
